Patents by Inventor Peter Ralph

Peter Ralph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6022953
    Abstract: Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: February 8, 2000
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, George Martin, Michael Piatak, James W. Larrick
  • Patent number: 6001582
    Abstract: Compositions involving I.kappa.B (i.e., inhibitor of Nuclear Factor-.kappa.B or NF-.kappa.B) and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 14, 1999
    Assignee: The University of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • Patent number: 6001605
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: December 14, 1999
    Assignees: Chiron Corporation, The University of North Carolina at Chapel Hill
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5994060
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 30, 1999
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5977323
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignees: Chiron Corporation, University of North Carolina at Chapel Hill
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5932537
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 3, 1999
    Assignee: Chiron Corporation
    Inventors: John S. Haskill, Peter Ralph, Joanna Mizen Watson
  • Patent number: 5874561
    Abstract: The present invention is directed to DNA, host cells and a vector encoding a protein with cytokine inhibitory activity, particularly IL-1 inhibitory activity. The protein encoded by the DNA of the present invention is particularly useful as an IL-1 antagonist.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 23, 1999
    Assignee: Chiron Corporation/Chapel Hill North Carolina
    Inventors: John Stephen Haskill, George Martin, Peter Ralph
  • Patent number: 5872095
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 16, 1999
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph
  • Patent number: 5858688
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignees: Chiron Corporation, University of North Carolina at Chapel Hill
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5846714
    Abstract: Compositions and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 8, 1998
    Assignees: Chiron Corporation, Unversity of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • Patent number: 5837229
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: November 17, 1998
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, Kong T. Chong
  • Patent number: 5830756
    Abstract: Compositions and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 3, 1998
    Assignees: Chiron Corporation, University of North Carolina
    Inventors: John Stephen Haskill, Albert S. Baldwin, Jr., Peter Ralph
  • Patent number: 5824549
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 20, 1998
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph
  • Patent number: 5817306
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 6, 1998
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph
  • Patent number: 5747444
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 5, 1998
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph
  • Patent number: 5725850
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: March 10, 1998
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, Kong T. Chong, James Devlin, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring, Sylvia Hsieh Ma
  • Patent number: 5635175
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: June 3, 1997
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, Kong T. Chong
  • Patent number: 5614183
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: March 25, 1997
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, Kong T. Chong
  • Patent number: 5567611
    Abstract: Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: October 22, 1996
    Assignee: Cetus Onocology Corporation
    Inventors: Peter Ralph, George Martin, Michael Piatak, James W. Larrick
  • Patent number: 5556620
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: September 17, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Peter Ralph, Sharon Auckerman, James Devlin